Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monte Rosa Therapeutics (GLUE) Depreciation & Amortization (CF) (2023 - 2025)

Monte Rosa Therapeutics (GLUE) has 3 years of Depreciation & Amortization (CF) data on record, last reported at $2.1 million in Q3 2025.

  • For Q3 2025, Depreciation & Amortization (CF) changed 0.38% year-over-year to $2.1 million; the TTM value through Sep 2025 reached $8.3 million, up 5.31%, while the annual FY2024 figure was $8.1 million, 30.52% up from the prior year.
  • Depreciation & Amortization (CF) reached $2.1 million in Q3 2025 per GLUE's latest filing, down from $2.2 million in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $2.2 million in Q2 2025 and bottomed at $1.2 million in Q1 2023.
  • Average Depreciation & Amortization (CF) over 3 years is $1.9 million, with a median of $2.0 million recorded in 2025.
  • Peak YoY movement for Depreciation & Amortization (CF): soared 58.33% in 2024, then decreased 0.38% in 2025.
  • A 3-year view of Depreciation & Amortization (CF) shows it stood at $1.8 million in 2023, then rose by 11.65% to $2.1 million in 2024, then increased by 1.65% to $2.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Depreciation & Amortization (CF) were $2.1 million in Q3 2025, $2.2 million in Q2 2025, and $2.0 million in Q1 2025.